Mini-Reviews in Medicinal Chemistry, Vol 15, No 1 (2015)

Font Size:  Small  Medium  Large

: Antiviral medication in sexually transmitted diseases. Part II: HIV

Dr. Anna Majewska, Dr. Beata Mlynarczyk-Bonikowska, Prof. Magdalena Malejczyk, Prof. Grazyna Mlynarczyk, Prof. Slawomir Majewski


This is a second part of a review under a main title Antiviral medication in sexually transmitted diseases. In the part we published in Mini Rev Med Chem. 2013,13(13):1837-45, we have described mechanisms of action and mechanism of resistance to antiviral agents used in genital herpes and genital HPV infection. The Part II review focuses on therapeutic options in HIV infection. In 1987, 6 years after the recognition of AIDS, the FDA approved the first drug against HIV - zidovudine. Since then a lot of antiretroviral drugs are available. The most effective treatment for HIV is highly active antiretroviral therapy - a combination of several antiretroviral medicines that cause a reduction of HIV blood concentration and often results in substantial recovery of impaired immunologic function. At present there are over 20 drugs licensed and used for the treatment of HIV/AIDS, and these drugs are divided into one of six classes. Investigational agents include GS-7340, the prodrug of tenofovir and BMS-663068 - the first in a novel class of drugs that blocks the binding of the HIV gp120 to the CD4 receptor. In Part III, we will depict the therapeutic options in other sexually transmitted infections: hepatitis B and C. In 2014 passes 25th anniversary of the identification of the hepatitis C virus. At the end of 2013 in some countries two new medicines (simeprevir and sofosbuvir) were approved for the treatment. They are the novel promising therapeutic options in the treatment of chronic hepatitis C.


  • There are currently no refbacks.